Further Allergy M&A On The Cards?
This article was originally published in Scrip
Consolidation in the allergy therapy market looks set to continue following the recent merger of Stallergenes and Greer. Rumor has it that Germany's Merck may be about to sell its Allergopharma unit, which specializes in allergen immunotherapy, in which the cause rather than the symptoms of allergy are targeted.
Register for our free email digests: